Last reviewed · How we verify
Administration of Corneal Anesthesia — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tetracaine Hydrochloride | TETRACAINE | Alcon Labs | Ester Local Anesthetic | Sodium channel protein type 7 subunit alpha | 2005-01-01 | |
| Proxymetacaine | Proxymetacaine | Medical University of Silesia | Amine oxidase [flavin-containing] A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 10 subunit alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Alcon Labs · 1 drug in Administration of Corneal Anesthesia
- Medical University of Silesia · 1 drug in Administration of Corneal Anesthesia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Administration of Corneal Anesthesia:
- Administration of Corneal Anesthesia treatment updates — RSS
- Administration of Corneal Anesthesia treatment updates — Atom
- Administration of Corneal Anesthesia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Administration of Corneal Anesthesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/administration-of-corneal-anesthesia. Accessed 2026-06-10.
Related
- Administration of Corneal Anesthesia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing